Detection of IDH1 mutation in the plasma of patients with glioma
@article{Boisselier2012DetectionOI,
title={Detection of IDH1 mutation in the plasma of patients with glioma},
author={Blandine Boisselier and Jaime G{\'a}llego P{\'e}rez-Larraya and Marta Rossetto and Marianne Labussi{\`e}re and Pietro Ciccarino and Yannick Marie and Jean-Yves Delattre and Marc Sanson},
journal={Neurology},
year={2012},
volume={79},
pages={1693 - 1698}
}Objective: The IDH1R132H mutation is both a strong prognostic predictor and a diagnostic hallmark of gliomas and therefore has major clinical relevance. Here, we developed a new technique to detect the IDH1R132H mutation in the plasma of patients with glioma. Methods: Small-size DNA (150–250 base pairs) was extracted from the plasma of 31 controls and 80 patients with glioma with known IDH1R132H status and correlated with MRI data. The IDH1R132H mutation was detected by a combination of…
Topics from this paper
61 Citations
The clinical use of IDH1 and IDH2 mutations in gliomas
- Medicine, BiologyExpert review of molecular diagnostics
- 2018
The role of IDH mutations in clinical practice as a diagnostic, prognostic and predictive biomarker, and as a potential therapeutic target is emphasized and the routine use of noninvasive techniques for detection and monitoring of the IDH status remains challenging.
2-Hydroxyglutarate as a biomarker in glioma patients
- Medicine
- 2014
Analysis of R_2HG derived from individual plasma and urine 2HG levels is possible to discriminate glioma patients with and without IDH mutation, in particular in high grade gliomas.
Current and future tools for determination and monitoring of isocitrate dehydrogenase status in gliomas
- Biology, MedicineCurrent opinion in neurology
- 2018
These new techniques open avenues for non invasive diagnostic of glioma in patients not amenable to biopsy, in the preoperative setting and also during patients follow-up for evaluation of treatment response and prediction of recurrence.
Diagnostic value of circulating tumor DNA in molecular characterization of glioma
- Biology, MedicineMedicine
- 2020
Abstract Introduction: Circulating tumor DNA (ctDNA) has provided a minimally invasive approach for the detection of genetic mutations in glioma. However, the diagnostic value of ctDNA in glioma…
IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma.
- Medicine, BiologyNeuro-oncology
- 2013
The production of 2-hydroxyglutarate and enhanced NADP+ levels in tumor cells with mutant IDH1/2 suggest mechanisms through which these mutations contribute to tumorigenesis, which may lead to development of a new molecular classification system and novel therapies.
From genomics to the clinic: biological and translational insights of mutant IDH1/2 in glioma.
- BiologyNeurosurgical focus
- 2013
Rapidly emerging work on the consequences of mutant IDH1 protein expression suggests that its neomorphic enzymatic activity catalyzing the production of the oncometabolite 2-hydroxyglutarate influences a range of cellular programs that affect the epigenome, transcriptional programs, hypoxia-inducible factor biology, and development.
Genetics and Epigenetics of Glioblastoma: Applications and Overall Incidence of IDH1 Mutation
- MedicineFront. Oncol.
- 2016
Glioblastoma is the most fatal brain cancer found in humans. Patients suffering from glioblastoma have a dismal prognosis, with a median survival of 15 months. The tumor may develop rapidly de novo…
Detection of EGFRvIII mutant DNA in the peripheral blood of brain tumor patients
- Medicine, BiologyJournal of Neuro-Oncology
- 2013
A semi-quantitative blood biomarker may represent a strategy to screen patients for an anti-EGFRvIII therapy and monitor the patients’ response to treatment, and its level seems to correlate with the extent of the tumor resection.
Blood-based biomarkers for the diagnosis and monitoring of gliomas.
- Medicine, BiologyNeuro-oncology
- 2018
The ability to obtain serial "liquid biopsies" will provide unique opportunities to study the evolution of tumors and mechanisms of treatment resistance and monitor for mutational changes in response to therapy.
Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma
- Biology, MedicineActa neuropathologica communications
- 2015
The results support the translational potential of immunotherapeutic targeting of gliomas carrying IDH1 mutations and led to intratumoral up-regulation of IFN-γ, granzyme-b and perforin-1 and down- regulation of TGF-β2 and IL-10.
References
SHOWING 1-10 OF 23 REFERENCES
IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas
- MedicineClinical Cancer Research
- 2009
IDH1 mutations are a strong predictor of a more favorable prognosis and a highly selective molecular marker of secondary glioblastomas that complements clinical criteria for distinguishing them from primary gliOBlastomas.
Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.
- Biology, MedicineJournal of clinical oncology : official journal of the American Society of Clinical Oncology
- 2009
This study indicates that IDH1 codon 132 mutation is closely linked to the genomic profile of the tumor and constitutes an important prognostic marker in grade 2 to 4 gliomas.
COLD PCR HRM: a highly sensitive detection method for IDH1 mutations
- BiologyHuman mutation
- 2010
The p.Arg132His mutation of isocitrate dehydrogenase 1 (IDH1R132H) is a frequent alteration and a major prognostic marker in gliomas. However, direct sequencing of highly contaminated tumor samples…
Methylated tumor-specific DNA as a plasma biomarker in patients with glioma.
- Medicine, BiologyCancer investigation
- 2004
Patients with systemic malignancies have substantial quantities of tumor-specific DNA in their plasma which may serve as a potential biomarker for tumor burden, and in over 60 percent of these patients the same methylated promoters present in the tumor also were found in the plasma.
Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy
- Medicine, BiologyJournal of Neuro-Oncology
- 2011
Water-suppressed proton (1H) MRS provides a non-invasive measure of 2-HG in gliomas, and may serve as a potential biomarker for patients with IDH1 mutant brain tumors.
IDH1 and IDH2 Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendroglial Tumors: A Report of the European Organization for Research and Treatment of Cancer Brain Tumor Group
- Medicine, BiologyClinical Cancer Research
- 2010
In this homogeneously treated group of anaplastic oligodendroglioma patients, the presence of IDH1 mutations was found to carry a very strong prognostic significance for OS but without evidence of a predictive significance for outcome to PCV chemotherapy.
Detection of 2-Hydroxyglutarate in IDH-Mutated Glioma Patients by In Vivo Spectral-Editing and 2D Correlation Magnetic Resonance Spectroscopy
- Medicine, BiologyScience Translational Medicine
- 2012
The authors show that in vivo brain imaging for genotyping cancer patients is a possibility—one that would avoid invasive clinical procedures and help doctors not only predict cancer outcomes but also effectively treat tumors on the basis of grade and genetic makeup.
IDH1 mutations at residue p.R132 (IDH1R132) occur frequently in high‐grade gliomas but not in other solid tumors
- BiologyHuman mutation
- 2009
The data indicate that cancer mutations affecting IDH1R132 are tissue‐specific, and suggest that it plays a unique role in the development of high‐grade gliomas.
Detection and quantification of mutations in the plasma of patients with colorectal tumors.
- Biology, MedicineProceedings of the National Academy of Sciences of the United States of America
- 2005
Patients with advanced colorectal cancers consistently contained mutant adenomatous polyposis coli (APC) DNA molecules in their plasma, which has implications for the mechanisms through which tumor DNA is released into the circulation and for diagnostic tests based on this phenomenon.
Serum DNA can define tumor-specific genetic and epigenetic markers in gliomas of various grades.
- Medicine, BiologyNeuro-oncology
- 2010
Serum DNA in glial tumors is informative for both LOH and aberrant gene promoter methylation analysis during the course of the disease, and the sensitivity is moderate and specificity is high for both low- and high-grade tumors.